Kodiak Sciences Inc (KOD)
Health Care ยท Biological Products, (No Diagnostic Substances)
Kodiak Sciences Inc (KOD) is listed on Nasdaq, where its shares have traded since October 4, 2018. SentiSense covers Kodiak Sciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Victor Perlroth is its chief executive officer. The company reports 124 employees, and its corporate website is www.kodiak.com.
About Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Latest reported results
Kodiak Sciences Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 191 institutions reported holding KOD, with 60.5 million shares worth $2.4 billion in aggregate. The largest reported holders were Baker Bros. Advisors, T. Rowe Price and BlackRock. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on KOD
- KOD sentiment: whether news and social coverage of Kodiak Sciences Inc leans bullish or bearish, and the stories driving it.
- KOD ownership: all 191 reporting institutions, plus insider and congressional trades.
- KOD financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Kodiak Sciences Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Kodiak Sciences Inc do?
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines.
What sector is KOD in?
SentiSense classifies Kodiak Sciences Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does KOD stock trade?
Kodiak Sciences Inc (KOD) is listed on Nasdaq, where its shares have traded since October 4, 2018.
Who is the CEO of Kodiak Sciences Inc?
Victor Perlroth is the chief executive officer of Kodiak Sciences Inc.